Why are you reporting this TALK?
Remibrutinib phase 2 trial reduce ESSDAI
Donald ThomasVisit
ard.bmj.com
to learn moreFebruary 15, 2024
17 hr
Channels
DiscoveryCardiologyCOVIDDermatologyEndocrinologyGastroenterologyHematologyHepatologyNephrologyNeurologyOncologyOphthalmologyEvery DayAMDDry Eye DiseaseEyeCan: A Canadian Lens on OphthalmologyVISIONS 2024ARVO 2024AAO 2023WIO 2022
Primary CarePulmonologyRheumatologyUrologyDescription
Remibrutinib phase 2 trial reduce ESSDAI